| 摘要 |
The invention relates to a pharmaceutical formulation containing 6- dimethylaminometh-yl-1-(3-methoxy-phenyl)- cyclohexane-1,3-diol or one of th e pharmaceutically acceptable salts thereof in a matrix, with delayed release of active ingredients. The matrix contains 1-80 wt. % of one or several hydrophilic or hydrophobic polymers as pharmaceutically acceptable matrix formulators and exhibits the following dissolution rate in vitro: 3-35 wt % (in relation to 100 wt. % active ingredients) 6-dimethylaminomethyl-1-(3- methoxy--phenyl)-cyclohexane-1,3-diol is released after 0.5 hrs, 5-50 wt. % 6- dimethylaminomethyl-1-(3-methoxy-phenyl)-cyclohexane-1,3-diol is released after 1 hr, 10-75 wt.- % 6-Dimethylaminomethyl-1-(3-methoxy--phenyl)- cyclohexane-1,3-diol is released after 2 hrs, 15-82 wt.- % 6- dimethylaminomethyl-1-(3-methoxy-phenyl)-cyclohexane-1,3-diol is released after 3 hrs, 30-97 wt.- % 6-dimethylaminomethyl-1-(3-methoxy--phenyl)- cyclohexane-1,3-diol is released after 6 hours, more than 50 wt.- % 6- Dimethylaminomethyl-1-(3-methoxy-phenyl)-cyclohexane-1,3- diol is released after 12 hours, more than 70 wt.- % 6- dimethylaminomethyl-1-(3-methoxy- phenyl)-cyclohexane-1,3-diol is released after 18 hours, more than 80 wt.- % 6- dimethylaminomethyl-1 -(3- methoxy-phenyl)-cyclohexane-1,3-diol is released after 24 hrs.
|
